Hit by disappointing clinical data in its lead program, based on an oligonucleotide-based technology, the board of ProNAi Therapeutics Inc. decided in the second half of 2016 to use its healthy balance sheet to license potentially transformative assets in emerging biology with the potential to be next generation therapeutics. Consequently, after assessing more than 200 assets across the globe, the company opted to in-license two DNA damage repair (DDR) programs and relaunch itself as Sierra Oncology.
ProNAI Defects From Oligos to DDR As Sierra Oncology
Sierra Oncology president and CEO Dr Nick Glover tells Mike Ward how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused of DNA damage repair (DDR) and $100m in the bank.
More from Anticancer
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
More from Therapy Areas
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.